These findings have shed new light on potential different therapeutic applications and strategies for targeting CSCs in NB, from the use of last-generation compounds as STAT3 inhibitors to the use of stromal cells as NB-MSCs as a tool for drug delivery. This evidence concerns the gene STAT3 and neuroblastoma.